Premium
Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic
Author(s) -
Exalto Lieza G.,
van der Flier Wiesje M.,
Scheltens Phillip,
Biessels Geert Jan
Publication year - 2010
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.2010.02854.x
Subject(s) - medicine , memory clinic , dementia , cerebrospinal fluid , diabetes mellitus , alzheimer's disease , disease , cognition , endocrinology , psychiatry
OBJECTIVES: To determine the association between markers of glycemia and cerebrospinal fluid (CSF) amyloid β 1–42 (Aβ42) and tau levels in patients attending a memory clinic. DESIGN: Cross‐sectional study. SETTING: Memory clinic. PARTICIPANTS: Two hundred forty‐five consecutive patients attending a memory clinic. Clinical diagnoses were subjective cognitive complaints (n=91), mild cognitive impairment (n=62), Alzheimer's disease (n=58), and other dementia (n=34). Twenty‐one patients had diabetes mellitus. MEASUREMENTS: Glycosylated hemoglobin (HbA1c); fasting blood glucose levels; and CSF levels of Aβ42, total tau, and p‐tau 181. RESULTS: In regression analyses across the whole study sample adjusted for age, sex, and diagnostic group, there was no relationship between HbA1c or fasting glucose and CSF tau, p‐tau 182, or Aβ42 levels. Stratification for diabetes mellitus did not change the results. CONCLUSION: These observations do not support the hypothesis that the association between dysglycemia and impaired cognitive functioning is mediated through aberrant amyloid or tau metabolism.